Investigation of the T cell metabolic reprogramming during immunotherapy in oncologic patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00023625

Enrollment

Registered

2020-12-01

Start date

2020-12-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C43

Interventions

Group 1: Patients with malignant melanoma, small cell lung cancer or bladder cancer who are scheduled to receive immune checkpoint inhibitor treatment. At the beginning of treatment, at the second adm

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: age >18 years, histologically confirmed malignant melanoma, small cell lung cancer or bladder cancer, no previous treatment with an immune checkpoint inhibitor, signed written consent form

Exclusion criteria

Exclusion criteria: previously diagnosed immunodeficiency syndrome

Design outcomes

Primary

Measure	Time frame
Extracellular acidification rate and oxygen consumption rate of T cells as determined by extracellular flux assays (Seahorse) at the beginning of treatment, at the second administration and at the first tumor staging	—

Secondary

Measure	Time frame
metabolomics and lipidomics of T cells, cytokine production	—

Countries

Germany

Contacts

Public ContactPetya Apostolova

Klinik für Innere Medizin I

petya.apostolova@uniklinik-freiburg.de+4976127034010

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026